Table 1.

Prostanoid receptor agonists relevant to defining antagonist profiles

Prostanoid receptor	Full agonist		Partial agonist
	High selectivity	Moderate selectivity
DP1	BW-245C		BW-192C86a
DP2	15(R) PGD2, 15(R)-15-methyl PGD213,14-dihydro-15-oxo PGD2
EP1	ONO-DI-004	17-Phenyl PGE2	Iloprostb,c
EP2	ONO-AE1-259, CAY-10399d	Butaprost-FA, CP-533536e19(R)-hydroxy PGE2f
EP3	ONO-AE-248, SC-46275	Sulprostone, MB-28767	ONO-AP-324g
EP4	ONO-AE1-329, tetrazolo PGE1h	(PGE2)i
FP	Fluprostenol, latanoprost-FA	Cloprostenol	AL-8810j,k,l
IP	Cicaprost	AFP-07, iloprost	Octimibatem, taprostenen
TP	STA2, U-46619		CTA2o, PTA2o,p, U-44069p

Information on the non-referenced agonists may be obtained from Jones (2004) and this journal's Guide to Receptors and Channels edited by Alexander et al. (2008). In older publications, fluprostenol = ICI-81008, cloprostenol = ICI-80996, cicaprost = ZK-96480 and iloprost = ZK-36374.

FA, free acid.

^aSeries of bicyclic-hydantoin prostanoids (Leff and Giles, 1992).

^bDong et al. (1986).

^cBoie et al. (1997).

^dTani et al. (2002).

^eParalkar et al. (2003).

^fWoodward et al. (1993a).

^gJones et al. (1998).

^hAnalogue 19a in Billot et al. (2003).

ⁱUtility on high-sensitivity EP₄ systems.

^jGriffin et al. (1999).

^kWoodward et al. (2007).

^lSharif et al. (2008).

^mMerritt et al. (1991a,b;).

ⁿChan and Jones (2004).

^oArmstrong et al. (1985).

^pJones et al. (1982).